EuroBiotech: More Articles of Note

A pile of newspapers

> The FDA cleared Sensorion (EPA:ALSEN) to start a Phase II trial of SENS-111 in acute severe vertigo. The regulatory nod positions Sensorion to start the trial before the end of the year. Sensorion is advancing the program on the strength of data from a 100-person Phase Ib study, which was seen as demonstrating the safety and pharmacokinetics of the H4R antagonist. Release

> Orexo (STO:ORX) reported data on its 1,080-person retrospective opioid dependency study. Of the 978 evaluable patients, 759 completed treatment and were negative for opioids at the time of the last drug test. “With the REZOLV study we strengthen our ability to engage with physicians and payers in optimizing and improving access to treatment of opioid dependence,” Orexo CEO Nikolaj Sørensen said in a statement. Release

> MorphoSys (ETR:MOR) began a Phase II/III trial of MOR208 in relapsed or refractory diffuse large B cell lymphoma (DLBCL). The CD19-targeting monoclonal antibody is currently being assessed in a Phase II safety evaluation ahead of the planned initiation of the Phase III component of the study next year. “With the start of the B-MIND clinical trial, we now have two combination studies ongoing with MOR208 in relapsed/refractory DLBCL,” MorphoSys Chief Development Officer Dr. Arndt Schottelius said in a statement. Release

> Futura Medical (LON:FUM) posted data from a trial of its topical erectile dysfunction drug, sending its share price up close to 200% over the following trading sessions. In the 232-subject trial, the drug, MED2002, was associated with a statistically significant improvement in erectile function compared to the placebo. Futura, which has a market cap of £90 million ($120 million) following the surge, plans to use the data as the basis for its commercialization strategy. Release

> C4X Discovery (LON:C4XD) raised £5 million ($6.7 million) to advance its pipeline toward the clinic, while also starting work on the development of four new medicines. New investors Calculus Capital and Polar Capital contributed most of the money. Release 

> Vectura (LON:VEC) rethought its pipeline priorities following its merger with SkyePharma. SKP-2075, a Phase I ready theophylline-inhaled corticosteroid combination, is the biggest victim of the rethink. Vectura is halting investment in SKP-2075 to free up resources to spend on pressurized metered dose and dry powder generics, as well as JAK inhibitor VR588. Release